About the Conference
The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
The Union League of Philadelphia 140 South Broad Street Philadelphia, PA 19102 Tel: (215) 405-9578 www.unionleague.org/
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.
Industry News from BioCentury
- Dezima CETP inhibitor meets endpoint in dyslipidemia trialDezima Pharma B.V. (Naarden, the Netherlands) said TA-8995 (DEZ-001) alone or in combination with statin therapy met the primary endpoint vs. placebo in the 364-patient Phase IIb TULIP trial to treat dyslipidemia. The primary endpoint was a composite of the change from baseline in LDL-C and HDL-C at week 12.
Dezima plans to publish full data in the coming months and start a Phase III trial next year. The company has exclusive, worldwide rights, excluding certain Asian territories, to the cholesteryl ester transfer protein (CETP) inhibitor from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) (see BioCentury, Jan. 28, 2013).
Two other CETP inhibitors are already in Phase III trials: anacetrapib (MK-0859) from Merck & Co. Inc. (NYSE:MRK) and evacetrapib (LY2484595) from Eli Lilly and Co. (NYSE:LLY).
Industry News from PharmAsia
- Japan’s IPR Text Flagged Ahead of Asian Trade MeetJust ahead of a meeting of participating countries of the Asian Regional Comprehensive Economic Partnership (RCEP) in Myanmar, pro-health groups have cautioned India about "speedily" tabled intellectual property rights (IPR)-related proposals by Japan, which they claim could undermine public health safeguards in India's patent law.<img src="http://feeds.feedburner.com/~r/_PharmAsiaNews/~4/B_Kc8nalOqE" height="1" width="1" />